title: Intracellular EP2 prostanoid receptor promotes cancer-related phenotypes in PC3 cells.
abstract: Prostaglandin E2 (PGE2) and hypoxia-inducible factor-1α (HIF-1α) affect many mechanisms that have been involved in the pathogenesis of prostate cancer (PC). HIF-1α, which is up-regulated by PGE2 in LNCaP cells and PC3 cells, has been shown to contribute to metastasis and chemo-resistance of castrate-resistant PC (a lethal form of PC) and to promote in PC cells migration, invasion, angiogenesis and chemoresistance. The selective blockade of PGE2-EP2 signaling pathway in PC3 cells results in inhibition of cancer cell proliferation and invasion. PGE2 affects many mechanisms that have been shown to play a role in carcinogenesis such as proliferation, apoptosis, migration, invasion and angiogenesis. Recently, we have found in PC3 cells that most of these PGE2-induced cancer-related features are due to intracellular PGE2 (iPGE2). Here, we aimed to study in PC3 cells the role of iPGE2-intracellular EP2 (iEP2)-HIF-1α signaling in several events linked to PC progression using an experimental approach involving pharmacological inhibition of the prostaglandin uptake transporter and EGFR and pharmacological and genetic modulation of EP2 receptor and HIF-1α. We found that iPGE2 increases HIF-1α expression through iEP2-dependent EGFR transactivation and that inhibition of any of the axis iEP2-EGFR-HIF-1α in cells treated with PGE2 or EP2 agonist results in prevention of the increase in PC3 cell proliferation, adhesion, migration, invasion and angiogenesis in vitro. Of note, PGE2 induced EP2 antagonist-sensitive DNA synthesis in nuclei isolated from PC3 cells, which indicates that they have functional EP2 receptors. These results suggest that PGE2-EP2 dependent intracrine mechanisms involving EGFR and HIF-1α play a role in PC.
authors.affiliation: Departamento de Biología de Sistemas, Facultad de Medicina, Universidad de Alcalá, Alcalá de Henares, 28871, Madrid, Spain, anab.fernandez@uah.es.
authors.forename: Ana Belén
authors.initials: AB
authors.lastname: Fernández-Martínez
authors.forename: Javier
authors.initials: J
authors.lastname: Lucio-Cazaña
mesh_terms: D000704:Analysis of Variance; D015153:Blotting, Western; D001973:Bromodeoxyuridine; D002448:Cell Adhesion / Q000502:physiology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D049109:Cell Proliferation / Q000502:physiology; D015232:Dinoprostone / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism*; D008297:Male; D008856:Microscopy, Fluorescence; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D010641:Phenotype; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D058307:Receptors, Prostaglandin E, EP2 Subtype / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D013778:Tetrazolium Salts; D013844:Thiazoles
chemical_list: C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D058307:Receptors, Prostaglandin E, EP2 Subtype; D013778:Tetrazolium Salts; D013844:Thiazoles; C022616:thiazolyl blue; D001973:Bromodeoxyuridine; D015232:Dinoprostone
references.citation: Cell Death Differ. 2011 Mar;18(3):528-37
references.pmid: 20966963
references.citation: Carcinogenesis. 2009 Mar;30(3):377-86
references.pmid: 19136477
references.citation: Cancer Res. 2008 Oct 1;68(19):7750-9
references.pmid: 18829529
references.citation: Urology. 2006 Dec;68(6):1360-5
references.pmid: 17169665
references.citation: Nat Rev Mol Cell Biol. 2003 Aug;4(8):651-7
references.pmid: 12923527
references.citation: Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15792-7
references.pmid: 9861049
references.citation: Prostate Cancer Prostatic Dis. 2014 Mar;17(1):10-7
references.pmid: 24518515
references.citation: J Biol Chem. 2007 Apr 20;282(16):11613-7
references.pmid: 17329241
references.citation: Endocrinology. 2013 May;154(5):1768-79
references.pmid: 23515290
references.citation: Mol Carcinog. 2007 Nov;46(11):912-23
references.pmid: 17427962
references.citation: Cancer Lett. 2012 May 28;318(2):124-34
references.pmid: 22261334
references.citation: Peptides. 2009 Dec;30(12):2357-64
references.pmid: 19772879
references.citation: Science. 1995 May 12;268(5212):866-9
references.pmid: 7754369
references.citation: Can J Physiol Pharmacol. 2006 Mar-Apr;84(3-4):377-91
references.pmid: 16902584
references.citation: Int J Biochem Cell Biol. 2010 Feb;42(2):198-201
references.pmid: 19788928
references.citation: J Pharmacol Exp Ther. 2013 Feb;344(2):360-7
references.pmid: 23192657
references.citation: Circ Res. 2002 Apr 5;90(6):682-9
references.pmid: 11934836
references.citation: Am J Physiol Renal Physiol. 2002 Jun;282(6):F1103-10
references.pmid: 11997327
references.citation: Nat Rev Cancer. 2010 Mar;10(3):181-93
references.pmid: 20168319
references.citation: Nat Rev Cancer. 2007 Aug;7(8):621-7
references.pmid: 17611544
references.citation: Cancer Lett. 2003 Mar 10;191(2):125-35
references.pmid: 12618325
references.citation: Int J Biochem Cell Biol. 2011 Aug;43(8):1198-207
references.pmid: 21554977
references.citation: Trends Pharmacol Sci. 2003 Jul;24(7):335-40
references.pmid: 12871665
references.citation: J Biol Chem. 1999 May 28;274(22):15719-24
references.pmid: 10336471
references.citation: Oncogene. 2001 Mar 26;20(13):1594-600
references.pmid: 11313906
references.citation: Int J Biochem Cell Biol. 2015 Feb;59:52-61
references.pmid: 25462156
references.citation: Br J Cancer. 2012 Oct 23;107(9):1514-7
references.pmid: 23033009
references.citation: J Biol Chem. 2001 Mar 30;276(13):10548-55
references.pmid: 11136721
references.citation: Carcinogenesis. 2005 Jul;26(7):1170-81
references.pmid: 15498784
references.citation: Biochim Biophys Acta. 2014 Sep;1843(9):1997-2004
references.pmid: 24953041
references.citation: Mol Cell Biol. 1996 Sep;16(9):4604-13
references.pmid: 8756616
references.citation: Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):521-8
references.pmid: 21640519
references.citation: Int J Biochem Cell Biol. 2012 Dec;44(12):2185-93
references.pmid: 22964004
references.citation: Cell. 1997 Jan 10;88(1):109-19
references.pmid: 9019396
references.citation: J Clin Invest. 1996 Sep 1;98(5):1142-9
references.pmid: 8787677
references.citation: BMC Cancer. 2011 Apr 27;11:153
references.pmid: 21524287
references.citation: J Cell Biol. 1983 Nov;97(5 Pt 1):1648-52
references.pmid: 6630296
references.citation: BJU Int. 2000 Mar;85(4):451-62
references.pmid: 10691825
references.citation: Mol Pharmacol. 2004 Apr;65(4):973-8
references.pmid: 15044627
references.citation: J Urol. 2004 Feb;171(2 Pt 2):S36-40
references.pmid: 14713751
references.citation: PLoS One. 2013;8(1):e54251
references.pmid: 23342109
references.citation: Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8
references.pmid: 14641026
references.citation: Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:633-47
references.pmid: 12432949
references.citation: Trends Pharmacol Sci. 2013 Jul;34(7):413-23
references.pmid: 23796953
references.citation: Mol Cell Endocrinol. 2011 Jan 15;331(2):222-31
references.pmid: 20398727
references.citation: J Cell Biochem. 2004 Feb 15;91(3):459-77
references.pmid: 14755677
references.citation: N Engl J Med. 2003 Jul 24;349(4):366-81
references.pmid: 12878745
references.citation: Biochim Biophys Acta. 2013 Sep;1833(9):2029-38
references.pmid: 23644172
references.citation: Biochem Biophys Res Commun. 2002 Jan 11;290(1):249-55
references.pmid: 11779161
references.citation: Oncogene. 2007 Jul 26;26(34):4999-5009
references.pmid: 17369862
references.citation: Cell Mol Life Sci. 2015 Jun;72(11):2187-98
references.pmid: 25516021
references.citation: Life Sci. 2003 Dec 5;74(2-3):143-53
references.pmid: 14607241
references.citation: PLoS One. 2012;7(1):e29331
references.pmid: 22276108
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2004 Feb;70(2):149-65
references.pmid: 14683690
references.citation: Clin Cancer Res. 2003 Aug 1;9(8):3150-7
references.pmid: 12912967
references.citation: Mol Cancer Res. 2013 Apr;11(4):427-39
references.pmid: 23364535
references.citation: J Urol. 2004 Feb;171(2 Pt 2):S30-4; discussion S35
references.pmid: 14713750
references.citation: Cancer Prev Res (Phila). 2008 Jul;1(2):93-9
references.pmid: 19138942
references.citation: Science. 2002 Feb 1;295(5556):858-61
references.pmid: 11823643